Paper42100682
Lipid-lowering therapy for primary prevention of cardiovascular disease in adults aged 75 years and older: a narrative review.
Stephan D and 2 others. Int J Cardiol Cardiovasc Risk Prev, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Lipid-lowering therapy for primary prevention of cardiovascular disease in adults aged 75 years and older: a narrative review. Papers, record 42100682. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42100682
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Lipid-lowering therapy for primary prevention of cardiovascular disease in adults aged 75 years and older: a narrative review.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References41
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34458905 | 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. | Eur Heart J | 2021 | https://conductscience.org/library/papers/34458905 | PubMed |
| 2 | 25989805 | Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study. | BMJ | 2015 | https://conductscience.org/library/papers/25989805 | PubMed |
| 3 | 16129869 | A global clinical measure of fitness and frailty in elderly people. | CMAJ | 2005 | https://conductscience.org/library/papers/16129869 | PubMed |
| 4 | 34120185 | SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. | Eur Heart J | 2021 | https://conductscience.org/library/papers/34120185 | PubMed |
| 5 | 29318532 | Management of Statin Intolerance in 2018: Still More Questions Than Answers. | Am J Cardiovasc Drugs | 2018 | https://conductscience.org/library/papers/29318532 | PubMed |
| 6 | 38801776 | Benefits and Risks Associated With Statin Therapy for Primary Prevention in Old and Very Old Adults : Real-World Evidence From a Target Trial Emulation Study. | Ann Intern Med | 2024 | https://conductscience.org/library/papers/38801776 | PubMed |
| 7 | 24023757 | Long-term effects of statin treatment in elderly people: extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). | PLoS One | 2013 | https://conductscience.org/library/papers/24023757 | PubMed |
| 8 | 30712900 | Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. | Lancet | 2019 | https://conductscience.org/library/papers/30712900 | PubMed |
| 9 | 37082807 | Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale. | J Am Geriatr Soc | 2023 | https://conductscience.org/library/papers/37082807 | PubMed |
| 10 | 11253156 | Frailty in older adults: evidence for a phenotype. | J Gerontol A Biol Sci Med Sci | 2001 | https://conductscience.org/library/papers/11253156 | PubMed |
| 11 | 22836700 | A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. | J Nutr Health Aging | 2012 | https://conductscience.org/library/papers/22836700 | PubMed |
| 12 | 33196766 | Evaluation of Time to Benefit of Statins for the Primary Prevention of Cardiovascular Events in Adults Aged 50 to 75 Years: A Meta-analysis. | JAMA Intern Med | 2021 | https://conductscience.org/library/papers/33196766 | PubMed |
| 13 | 34854906 | Statin Discontinuation and Cardiovascular Events Among Older People in Denmark. | JAMA Netw Open | 2021 | https://conductscience.org/library/papers/34854906 | PubMed |
| 14 | 32187462 | Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32187462 | PubMed |
| 15 | 33410499 | Statin Use in Older Adults with Stable Atherosclerotic Cardiovascular Disease. | J Am Geriatr Soc | 2021 | https://conductscience.org/library/papers/33410499 | PubMed |
| 16 | 28531241 | Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial. | JAMA Intern Med | 2017 | https://conductscience.org/library/papers/28531241 | PubMed |
| 17 | 28813214 | Cognitive Function in a Randomized Trial of Evolocumab. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28813214 | PubMed |
| 18 | 34154589 | Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies. | BMC Med | 2021 | https://conductscience.org/library/papers/34154589 | PubMed |
| 19 | 26994063 | Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. | Am J Epidemiol | 2016 | https://conductscience.org/library/papers/26994063 | PubMed |
| 20 | 26039521 | Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26039521 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42100682
GET https://conductscience.org/api/papers/v1/42100682/references?page=2